Join this EASL Studio episode for a clinical perspective on advancing HCC care. Explore the realities of adjuvant therapies, emerging molecular targets, and strategies for curative conversion. Gain insights into practical innovations shaping the future and translating research into improved patient outcomes.
Moderator: Thomas Berg
Faculty: Tim Greten and Anna Saborowski
This EASL Studio is supported by Bayer.
EASL has received no input from Bayer with regards to the content of this programme.
Related episodes:
- EASL Studio S5E13: Basics in decision-making for liver cancer treatment
- EASL Studio from EASL Congress 2023: Highlights of the liver cancer research at EASL Congress 2023
- EASL Studio S4E16: Highlights from the EASL Liver Cancer Summit 2023
- EASL Studio S6E9: Therapy hierarchy in HCC: A new kid on the block